- Conditions
- Leukemia, Lymphoma
- Interventions
- carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 3,272
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hodgkin Lymphoma, Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
- Procedure · Drug · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 1 more
- Conditions
- Acute Kidney Injury
- Interventions
- AC607, Vehicle Only
- Biological
- Lead sponsor
- AlloCure Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • San Diego, California • Stanford, California + 17 more
- Conditions
- Hematopoietic Stem Cell Transplantations
- Interventions
- autoRIC®
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Cancer
- Interventions
- polymorphism analysis, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Lymphoma
- Interventions
- 131Iodine-Anti-B1 Radioimmunotherapy, BEAM
- Radiation · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
- Interventions
- bortezomib, rituximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, busulfan, lomustine, procarbazine hydrochloride, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Stanford, California • Evanston, Illinois + 2 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, nivolumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 13
- States / cities
- Duarte, California • Stanford, California • Boston, Massachusetts + 10 more
- Conditions
- Stem Cell Transplantation
- Interventions
- Thymic Transplantation for Recipients of UCB transplant
- Biological
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- AML, NHL, Hodgkin Disease, All, Myelodysplastic Syndrome
- Interventions
- Hyperbaric oxygen
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Lymphoma
- Interventions
- aldesleukin, recombinant human stem cell factor
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Columbus, Ohio
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
- Interventions
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
- Device · Drug
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cladribine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Venetoclax
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Disease Without Crisis
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Alessandra Biffi
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Barrett's Esophagus, Esophageal Adenocarcinoma
- Interventions
- EMR and RFA effect on stem cell marker expression in BE/EAC
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Graft Versus Host Disease
- Interventions
- total nodal irradiation, laboratory biomarker analysis, questionnaire administration
- Radiation · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
- Interventions
- Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2
- Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Craniocervical Injuries
- Interventions
- Alar treatment with BMC using anterior approach
- Procedure
- Lead sponsor
- Regenexx, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Broomfield, Colorado
- Conditions
- Leukemia
- Interventions
- therapeutic allogeneic lymphocytes, cyclosporine, cytarabine, fludarabine phosphate, methotrexate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant, Heart Rate Variability, Autonomic Nervous System, Stress, Mood, Psychological Distress, Emotion Regulation, Communication Research, Narrative
- Interventions
- Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Hodgkin Disease, Hodgkin Lymphoma
- Interventions
- Auto stem cell transplant, BEAM, 111In-daclizumab, 90Y-daclizumab
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Haploidentical Stem Cell Transplantation
- Drug · Other
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 16 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Treatment-Related Cancer
- Interventions
- Acupressure for Children in Treatment for a Childhood Cancer
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 5 Years to 24 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California